Top

Published in:

27-03-2024 | Thrombocytopenia | Original Article

Herombopag for the treatment of persistent thrombocytopenia following hematopoietic stem cell transplantation

Authors: Miao Zhou, Tongyu Li, Ping Zhang, Yanli Lai, Lixia Sheng, Guifang Ouyang

Published in: Annals of Hematology | Issue 5/2024

Abstract

Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) stands as a pivotal treatment for hematologic malignancies, often considered the sole effective treatment option. A frequent complication following allo-HSCT is poor graft function (PGF), with one of its primary manifestations being persistent thrombocytopenia (PT), comprising prolonged isolated thrombocytopenia (PIT) and secondary failure of platelet recovery (SFPR). Conventional treatment methods have had poor efficacy and a high transplantation-associated mortality rate. In recent years, the efficacy of eltrombopag has been reported in the treatment of post-transplantation PT, and additional thrombopoietin receptor agonists (TPO-RA) have been developed. Herombopag is a next-generation TPO-RA which has strong proliferation-promoting effects on human TPO-R-expressing cells (32D-MPL) and hematopoietic progenitor cells in vitro. We reviewed eighteen patients with transplantation-associated thrombocytopenia who received herombopag when eltrombopag was ineffective or poorly tolerated and evaluated its efficacy including effects on survival. Herombopag was administered at a median time of 197 days post-transplantation. Six patients achieved complete response (CR), with a median time to CR of 56 days. Five patients achieved partial response (PR), and the median time to PR was 43 days. Seven patients were considered to have no response (NR). The overall response (OR) rate was 61.1%, and the cumulative incidence (CI) of OR was 90.2%. No patients developed herombopag-associated grade 3–4 toxicity. The median follow-up period was 6.5 months. Twelve patients survived and six patients died, with an overall survival rate of 66.7%. This is the first study to demonstrate the efficacy and safety of herombopag in transplantation-associated thrombocytopenia after failing eltrombopag, introducing a new approach in the treatment of PT following allo-HSCT.

Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, Bouzas LF, Confer D, Greinix H, Horowitz M, Iida M, Lipton J, Mohty M, Novitzky N, Nunez J, Passweg J, Pasquini MC, Kodera Y, Apperley J, Seber A, Gratwohl A (2016) Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant 51(6):778–785. https://doi.org/10.1038/bmt.2016.18CrossRefPubMedPubMedCentral

Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, Gratwohl M, Bouzas LF, Confer D, Frauendorfer K, Gluckman E, Greinix H, Horowitz M, Iida M, Lipton J, Madrigal A, Mohty M, Noel L, Novitzky N, Nunez J, Oudshoorn M, Passweg J, van Rood J, Szer J, Blume K, Appelbaum FR, Kodera Y, Niederwieser D (2015) One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol 2(3):e91–100. https://doi.org/10.1016/s2352-3026(15)00028-9CrossRefPubMed

Yamazaki R, Kuwana M, Mori T, Okazaki Y, Kawakami Y, Ikeda Y, Okamoto S (2006) Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover. Bone Marrow Transplant 38(5):377–384. https://doi.org/10.1038/sj.bmt.1705444CrossRefPubMed

Kuzmina Z, Eder S, Böhm A, Pernicka E, Vormittag L, Kalhs P, Petkov V, Stary G, Nepp J, Knobler R, Just U, Krenn K, Worel N, Greinix HT (2012) Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia 26(4):746–756. https://doi.org/10.1038/leu.2011.257CrossRefPubMed

Kong Y, Song Y, Tang FF, Zhao HY, Chen YH, Han W, Yan CH, Wang Y, Zhang XH, Xu LP, Huang XJ (2018) N-acetyl-L-cysteine improves mesenchymal stem cell function in prolonged isolated Thrombocytopenia post-allotransplant. Br J Haematol 180(6):863–878. https://doi.org/10.1111/bjh.15119CrossRefPubMed

Sun YQ, Kong Y, Zhang XH, Wang Y, Shi MM, Song Y, Kong J, Fu HX, Yan CH, Xu LP, Liu KY, Huang XJ (2019) A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation. Platelets 30(8):994–1000. https://doi.org/10.1080/09537104.2018.1557613CrossRefPubMed

Bolwell B, Pohlman B, Sobecks R, Andresen S, Brown S, Rybicki L, Wentling V, Kalaycio M (2004) Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant 33(4):419–423. https://doi.org/10.1038/sj.bmt.1704330CrossRefPubMed

Zaja F, Geromin A, Patriarca F, Puglisi S, Cerno M, Sperotto A, Battista ML, Isola M, Fanin R (2011) Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant. Am J Hematol 86(9):790–792. https://doi.org/10.1002/ajh.22086CrossRefPubMed

Mahat U, Rotz SJ, Hanna R (2020) Use of Thrombopoietin receptor agonists in prolonged Thrombocytopenia after hematopoietic stem cell transplantation. Biology of blood and marrow transplantation: journal of the American Society for Blood and marrow transplantation. 26(3):e65–e73. https://doi.org/10.1016/j.bbmt.2019.12.003

10.

Huang A, Zhao X, Li M, Tang G, Fei Y, Wang R, Gao L, Ni X, Zhang W, Yang J, Hu X, Wang J (2020) Suppression of Hematopoietic Primitive Cells in patients with secondary failure of platelet recovery after Acute Graft-versus-host disease. Biology of blood and marrow transplantation: journal of the American Society for Blood and marrow transplantation. 26(10):1840–1854. https://doi.org/10.1016/j.bbmt.2020.06.003

11.

Di Buduo CA, Currao M, Pecci A, Kaplan DL, Balduini CL, Balduini A (2016) Revealing eltrombopag’s promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation. Haematologica 101(12):1479–1488. https://doi.org/10.3324/haematol.2016.146746CrossRefPubMedPubMedCentral

12.

Wen B, Zhang X, Chen S, Fan J, Yang S, Cai Y, Wang P, Zhang Q, Gu Q, Du X (2022) Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: a prospective, non-inferiority, randomized controlled trial. Hematol Oncol 40(4):777–786. https://doi.org/10.1002/hon.3017CrossRefPubMedPubMedCentral

13.

Masetti R, Vendemini F, Quarello P, Girardi K, Prete A, Fagioli F, Pession A, Locatelli F (2020) Eltrombopag for Thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children. Pediatr Blood Cancer 67(5):e28208. https://doi.org/10.1002/pbc.28208CrossRefPubMed

14.

Yuan C, Boyd AM, Nelson J, Patel RD, Varela JC, Goldstein SC, Ahmad S, Zhu X, Mori S (2019) Eltrombopag for treating Thrombocytopenia after allogeneic stem cell transplantation. Biology of blood and marrow transplantation: journal of the American Society for Blood and marrow transplantation. 25(7):1320–1324. https://doi.org/10.1016/j.bbmt.2019.01.027

15.

Rivera D, Bastida JM, Lopez-Corral L, Sanchez-Guijo F, Cabrero M, Martin A, Perez E, Lopez-Parra M, Avendaño A, Veiga A, Baile M, Arratibel N, Carrillo J, Vazquez L, Caballero MD, Gonzalez-Porras JR (2019) Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplant 54(5):757–761. https://doi.org/10.1038/s41409-018-0368-1CrossRefPubMed

16.

Syed YY (2021) Hetrombopag: first approval. Drugs 81(13):1581–1585. https://doi.org/10.1007/s40265-021-01575-1CrossRefPubMed

17.

Li T, Liu Q, Pu T, Liu J, Zhang A (2023) Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis. Expert Opin Pharmacother 24(6):763–774. https://doi.org/10.1080/14656566.2023.2198089CrossRefPubMed

18.

Peng G, He G, Chang H, Gao S, Liu X, Chen T, Li P, Han B, Miao M, Ge Z, Ge X, Li F, Li Y, Wang S, Wang Y, Shen Y, Zhang T, Zou J, Zhang F (2022) A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy. Therapeutic Adv Hematol 13:20406207221085197. https://doi.org/10.1177/20406207221085197CrossRef

19.

Zheng X, Zhang H, Guo W, Cao Y, Liu X, Zhai W, Zhang X, Wang F, Wei J, Yang D, Huang Y, Pang A, Feng S, Jiang E, Han M (2023) Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 110(5):527–533. https://doi.org/10.1111/ejh.13925CrossRefPubMed

20.

Broudy VC, Lin NL (2004) AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 25(2):52–60. https://doi.org/10.1016/j.cyto.2003.05.001CrossRefPubMed

21.

Cheloff AZ, Al-Samkari H (2019) Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med 10:313–321. https://doi.org/10.2147/jbm.s191790CrossRefPubMedPubMedCentral

22.

Xie C, Zhao H, Bao X, Fu H, Lou L (2018) Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist. J Cell Mol Med 22(11):5367–5377. https://doi.org/10.1111/jcmm.13809CrossRefPubMedPubMedCentral

23.

Yang G, Huang R, Yang S, Zhang X, Yang X, Chen H, Huang Z, Guo C, Pei Q, Tai Y, Shen Y, Huang J, Zou C (2020) Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers. Br J Clin Pharmacol 86(8):1528–1536. https://doi.org/10.1111/bcp.14259CrossRefPubMedPubMedCentral

24.

Wang Z, Chen L, Zhang F, Lu H, Chen X, Wen A, Luo J, Hu Y, Wang Y, Niu T, Zheng L (2020) First-in-patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura. J Thromb Haemostasis: JTH 18(11):3053–3060. https://doi.org/10.1111/jth.15078CrossRef

25.

Zhang F, Peng G, He G, Chang H, Gao S, Liu X, Chen T, Li P, Han B, Miao M (2020) A multicenter, open-label, single-arm, phase 2 study to evaluate the efficacy and safety of hetrombopag in patients with severe aplastic anemia (SAA). Blood 136:3–4. https://doi.org/10.1182/blood-2020-137319CrossRef

26.

Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, Cheng P, Huang R, Yang L, Hu J, Hou M, Yao Y, Liu L, Wang Y, Wu D, Zhang L, Zheng C, Shen X, Hu Q, Liu J, Jin J, Luo J, Zeng Y, Gao S, Zhang X, Zhou X, Shi Q, Xia R, Xie X, Jiang Z, Gao L, Bai Y, Li Y, Xiong J, Li R, Zou J, Niu T, Yang R, Hu Y (2021) A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. J Hematol Oncol 14(1):37. https://doi.org/10.1186/s13045-021-01047-9CrossRefPubMedPubMedCentral

27.

Hu Y, Yang R, Niu T, Mei H, Xiaofan L, Li Y, Zhou H, Feng Y, Gao G, Cheng P (2022) Switching from Eltrombopag to Hetrombopag in patients with primary Immune Thrombocytopenia (ITP): post-hoc analysis of a Multicenter, Randomized Phase III Trial. Blood 140(Supplement 1):5543–5545. https://doi.org/10.1182/blood-2022-162945CrossRef

Title: Herombopag for the treatment of persistent thrombocytopenia following hematopoietic stem cell transplantation
Authors: Miao Zhou
Tongyu Li
Ping Zhang
Yanli Lai
Lixia Sheng
Guifang Ouyang
Publication date: 27-03-2024
Publisher: Springer Berlin Heidelberg
Keywords: Thrombocytopenia
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Graft-Versus-Host Disease
Graft-Versus-Host Disease
Published in: Annals of Hematology / Issue 5/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-024-05711-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2024

Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with β-thalassemia

Palliative care for patients with hematologic malignancies in Germany: a nationwide survey on everyday practice and influencing factors from the perspective of treating physicians

Epidemiological features and a survival nomogram for primary lymphoma of the male genital tract

Validation of a Stenotrophomonas maltophilia bloodstream infection prediction score in the hematologic malignancy population

Autotaxin is a potential predictive marker for the development of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation

Is eryptosis druggable?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials